Network pharmacology-based study on the mechanism of Salvia miltiorrhiza in treatment of Parkinson's disease

doi:10.12092/j.issn.1009-2501.2019.06.001

Abstract

Abstract:

AIM: To predict and screen the active constituents of Parkinson's disease and its potential targets by using network pharmacology techniques, and to explore the mechanism of prevention and treatment of Salvia miltiorrhiza on multi-component group-multi-target group-disease of Parkinson's disease. METHODS: BATMAN-TCM was used to predict and screen the active components and target of Salvia miltiorrhiza. The components and target network of Salvia miltiorrhiza in Parkinson's disease were constructed by using Cytoscape software. The PPI network was constructed by STRING database, and the target GO was analyzed by KOBAS database. Enrichment and KEGG signaling pathways. RESULTS:The 124 active components of Salvia miltiorrhiza were screened and 11 targets related to Parkinson's disease were predicted, which were mainly related to ACHE, ADORA2A, AGTR1 and other targets. Ten of them had interactions, and were screened at P<0.05. A total of 1 112 GO biological processes were obtained, the functions of which involved processes such as dopamine metabolism, catechol-containing compound metabolism. 34 signal pathways were screened, and the first 20 KEGG pathways were related to dopaminergic synapses and neuroactive ligand-receptor interactions. CONCLUSION:The mechanism of multi-component-multi-target-multi-pathway treatment of Parkinson's disease from dopamine metabolism process and neuroactive ligand-receptor interaction is revealed, which provides theoretical support for targeted drug development and clarification mechanism.

Key words: Salvia miltiorrhiza, Parkinson's disease, network pharmacology, mechanism

CLC Number:

R741

ZHANG Shuijing, DU Zhongyan. Network pharmacology-based study on the mechanism of Salvia miltiorrhiza in treatment of Parkinson's disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 601-607.

References

［1］Kalia LV，Lang AE．Parkinson's disease［J］.Lancet，2015，386(9996) : 896-912.
［2］孙忠人,杨文明.神经病学［M］.2 版.北京:人民卫生出版社,2016:102-110.
［3］Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030［J］. Neurology, 2007, 68(5):384-386.
［4］Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review［J］. Jama, 2016, 311(16):1670-1683.
［5］黄少东, 梁健芬, 陈月桥,等. 中药复方联合复方左旋多巴治疗帕金森病的临床研究进展［J］. 湖南中医药大学学报,2018,38(12):1471-1475.
［6］赵荣博, 黄小波, 王倩, 等. 补肾解毒法治疗帕金森病轻度认知功能障碍的临床疗效观察［J］. 中华中医药杂志, 2018, 33(7): 3172-3175.
［7］韦一佛, 陈路, 张亚男, 等. 滋肾益髓方对帕金森病小鼠分子伴侣介导的自噬途径的影响［J］. 中华中医药杂志, 2018 (9): 106.
［8］杨明会, 李敏, 窦永起, 等. 补肾活血颗粒对帕金森病患者脑内多巴胺水平的影响［J］.中医杂志, 2011, 52(4):299-302.
［9］Wang JG, Bondy SC, Zhou L, et al. Protective effect of Tanshinone IIA against infarct size and increased HMGB1, NFκB, GFAP and apoptosis consequent to transient middle cerebral artery occlusion［J］. Neurochemical Research, 2014, 39(2):295-304.
［10］郑鸿燕,曾水林,李涛.丹参注射液促帕金森病移植神经元存活的实验研究［J］.药学与临床研究,2004,12(2):1-3.
［11］Hopkins AL. Network pharmacology: the next paradigm in drug discovery［J］. Nat Chem Biol, 2008, 4(11):682-690.
［12］李泮霖,苏薇薇.网络药理学在中药研究中的最新应用进展［J］.中草药,2016,47(16):2938-2942.
［13］Liu CX,Liu R,Fan HR,et al.Network Pharmacology bridges traditional application and modern development of traditional Chinese medicine［J］. Chinese Herbal Medicines, 2015, 7(1):3-17.
［14］Liu Z, Guo F, Wang Y, et al. BATMAN-TCM: a bioinformatics analysis tool for molecular mechanism of traditional chinese medicine［J］.Sci Rep,2016, 6:21146.
［15］张彦琼, 李梢. 网络药理学与中医药现代研究的若干进展［J］. 中国药理学与毒理学杂志, 2015,29(6):883-892.
［16］姚晓萌, 曲庆洋, 向冬生, 等. 多巴胺D1受体阻断剂SCH23390对帕金森病大鼠脚内核电活动的影响［J］. 中华神经医学杂志, 2018, 17(4):331-336.
［17］丁家琦, 陈晓莉, 林家骥,等. 敲低小鼠中脑神经元多巴胺D2受体使其生脂基因表达上调［J］. 细胞与分子免疫学杂志, 2018, 34(1):28-34.
［18］潘天虹. 多巴胺及多巴胺转运蛋白与帕金森病［J］. 中国细胞生物学学报, 2001, 23(3):166-168.
［19］Aflaki E, Borger DK, Moaven N, et al. A new glucocerebrosidase chaperone reduces α-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with gaucher disease and Parkinsonism［J］. J Neurosci, 2016,36(28):7441-7452.

[1]	YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan. Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
[2]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[3]	LI Shuang, HAN Shuzhen, DAI Yuting, XIU Minghui, DU Xianqin, HE Jianzheng, LIN Xingyao. Progress in the prevention and treatment of traditional Chinese medicine based on the mechanism of intestinal injury of various chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 583-593.
[4]	CAO Fang, QIN Kairong, ZHENG Guoshuang, ZHAO Dewei. Exploring the intervention mechanism of Ginkgo biloba for steroid-induced necrosis of the femoral head based on network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 266-275.
[5]	ZHANG Li, LIN Xingyao, SHANG Yun, WANG Qiang. Progress on the pathological mechanism and treatment of frostbite [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 347-354.
[6]	HOU Xiaoyu, LENG Yufang, CAO Xuefen, LV Xingjiao, HAN Xiaoxia, Janvier NIBARUTA, LIU Yongqiang. Network analysis and experimental verification of Schisandrin B reduces intestinal ischemia reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 147-154.
[7]	LI Xinyu, HUANG Xin. State of clinical application of meloxicam [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 189-197.
[8]	CHEN Yulin, JIANG Hugang, WANG Xinqiang, LIU Kai, LI Yingdong, AN Tao, ZHAO Xinke. Effects and mechanism of Ginseng Yixin granules (QSYXG) for heart failure with preserved ejection fraction based on the network pharmacology and molecular docking strategy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1081-1092.
[9]	LIU Dan, LIU Ming, JIN Liangyou, PAN Juan, XIN Haoru, LIU Mengyuan, LI Xin, ZHENG Kun, FENG Xiaoling. Research progress on the antitumor activity of costunolide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1168-1176.
[10]	SHAO Mingkun, LIU Rong, SUN Pin, GUAN Shui, LIAO Bingcan, LI Sha, CONG Tao, LIANG Kai, MA Hui, SUN Changkai. Human body networks mechanisms of melatonin and its clinical applications [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1031-1040.
[11]	ZHANG Wei, WANG Yingbin, CAO Lu, LIU Yan, ZHANG Li, LIU Jieting. Research progress of autophagy in intestinal ischemia-reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1061-1066.
[12]	WANG Liang, ZHANG Hulin, WANG Xiaomin, YANG Chaoqiang, WANG Yican, LAI Xueqian. Research progress on the mechanism of iron overload in the occurrence and development of osteoarthritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1075-1080.
[13]	HAN Xiaoxia, LENG Yufang, LV Xingjiao, HOU Xiaoyu, CAO Xuefen, Janvier NIBARUTA. Research progress on the role and mechanism of irisin in organ ischemia/reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 886-891.
[14]	DU Jie, ZHAO Tingting, WANG Dalong, CHEN Xiaodong, LIU Kexin, WU Jingjing. Role and research progress of CYP46A1 in neurodegenerative diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 925-935.
[15]	LI Miao, YU Qinwei, JIANG Zhenzhou, ZHANG Luyong, . Regulatory mechanism of LDLR and research progress of its related diseases and drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 946-954.